# Compound Edaravone Injection for Acute Ischemic Stroke

Study · id `cardio:ct-nct01929096` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01929096](<https://clinicaltrials.gov/study/NCT01929096>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01929096

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

## Technical summary

Registry record NCT01929096. Randomized; quadruple masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 400 participants (enrolled count; ClinicalTrials.gov record NCT01929096, source copy `cardio:ctgov-nct01929096-2015-07-03`, retrieved 2026-10-26)
- Start date: 2013-08 (registry gives no type) (ClinicalTrials.gov record NCT01929096, source copy `cardio:ctgov-nct01929096-2015-07-03`, retrieved 2026-10-26)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01929096, source copy `cardio:ctgov-nct01929096-2015-07-03`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01929096, source copy `cardio:ctgov-nct01929096-2015-07-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01929096, source copy `cardio:ctgov-nct01929096-2015-07-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01929096-2015-07-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Compound Edaravone Injection for Acute Ischemic Stroke
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Compound Edaravone Injection
- Intervention (Drug): Edaravone Injection
- Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-simcere-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial (`cardio:pubmed-31709115`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9ab31c966a9fea1d6d39bd2808816d63ec0b54fa11dca3f60760a39e81dc1900
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
